Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

References

• Altmann SW, Davis HR, Zhu LJ, G et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201–4
   PubMed Web of Science ®Google Scholar
• van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157–63
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748–54
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;34:409–17
   Google Scholar
• Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943–8
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729–41
   PubMed Web of Science ®Google Scholar
• Ezzet F, Krishna G, Wexler D, Statkevich P, Kosoglou T, Batra V. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001;23:871–85
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in subjects with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–30
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092–7
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309–19
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001;37(Suppl A):229A [abstract]
   Google Scholar
• Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications. Atherosclerosis 2001;2(Suppl):89 [abstract]
   Google Scholar
• Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793–802
   PubMed Web of Science ®Google Scholar
• Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001;50: 1234–41
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Statkevich P, Zhu Y, Kosoglou T, Affrime MB, Salfi M, Patrick J. Ezetimibe (SCH 58235) does not affect the pharmacokinetics of simvastatin. Clin Pharmacol Ther 2000;67:146 [abstract]
   Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc; 1982. p. 409–17
   Google Scholar
• Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001;3(Suppl E):E11–6
   Google Scholar
• Physician’s Desk Reference. MEVACOR tablets (lovastatin) product information. Montvale, NJ: Medical Economics Company, Inc., 1999. p. 1834
   Google Scholar
• Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41:943–9
   PubMed Web of Science ®Google Scholar
• Knopp RH, Retzlaff B, Walden C, Fish B, Buck B, McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects (44564E). Proc Soc Exp Biol Med 2000; 225:191–9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Statkevich P, Kosoglou T, Boutros T, Maxwell SE, Patrick J, Batra V. Effect of age on the pharmacokinetics of ezetimibe, a cholesterol absorption inhibitor. AAPS PharmSci Supplement 2000;2:2082 [abstract]
   Google Scholar
• Zhu Y, Statkevich P, Kosoglou T, Maxwell SE, Anderson L, Patrick JE, Batra V. Lack of pharmacokinetic interaction between ezetimibe and atorvastatin. Clin Pharmacol Ther 2001;69:68 [abstract]
   Google Scholar
• Reyderman L, Statkevich P, Kosoglou T, Pember LJ, Maxwell SE, Caceres M, Batra VK. No pharmacokinetic drug interaction between ezetimibe and either cerivastatin or fluvastatin. AAPS PharmSci Supplement 2001;3(3) [online abstract]. Available from http://www.aapspharmaceutica.com/search/abstract_view.asp?id=331
   Google Scholar
• Reyderman L, Kosoglou T, Maxwell SE, Boutros T, Pember LJ, Batra VK, Statkevich P. Lack of pharmacokinetic drug interaction between ezetimibe and fenofibrate. AAPS PharmSci Supplement 2001;3(3) [online abstract]. Available from http://www.aapspharmaceutica.com/search/abstract_view.asp?id=326
   Google Scholar
• Reyderman L, Kosoglou T, Statkevich P, et al. No pharmacokinetic drug interaction between ezetimibe and lovastatin. Clin Pharmacol Ther 2001;69:66 [abstract]
   Google Scholar
• Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418–24
   PubMed Web of Science ®Google Scholar